Sudden cardiac death and antipsychotic drugs: Do we know enough?

Archives of General Psychiatry

Volumn 58, Issue 12, 2001, Pages 1168-1171

  Zarate C A , Jr ^a  

^a NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIARRHYTHMIC AGENT; ANTIBIOTIC AGENT; ANTIDEPRESSANT AGENT; ANTIFUNGAL AGENT; ANTIHISTAMINIC AGENT; ANTIMALARIAL AGENT; CHLORPROMAZINE; CHOLINERGIC RECEPTOR BLOCKING AGENT; CLOZAPINE; CYTOCHROME P450; DIURETIC AGENT; DROPERIDOL; FLUPHENAZINE; HALOPERIDOL; INSULIN; MACROLIDE; MESORIDAZINE; NEUROLEPTIC AGENT; OLANZAPINE; PIMOZIDE; PROCHLORPERAZINE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RISPERIDONE; SEROTONIN AGONIST; SEROTONIN ANTAGONIST; THIORIDAZINE; TRICYCLIC ANTIDEPRESSANT AGENT; TRIFLUOPERAZINE; UNINDEXED DRUG; VASODILATOR AGENT;

CARDIOTOXICITY; CLINICAL ARTICLE; CLINICAL TRIAL; DEPRESSION; DRUG BLOOD LEVEL; DRUG INDUCED DISEASE; DRUG OVERDOSE; DRUG SAFETY; FOOD AND DRUG ADMINISTRATION; HEART ARRHYTHMIA; HEART DEATH; HUMAN; LONG QT SYNDROME; MENTAL DISEASE; MORTALITY; NOTE; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PSYCHOPHARMACOTHERAPY; RISK ASSESSMENT; SUDDEN DEATH;

EID: 0035200277     PISSN: 0003990X     EISSN: None     Source Type: Journal    
DOI: 10.1001/archpsyc.58.12.1168     Document Type: Note

References (43)

1. Cardiovascular adverse effects of antipsychotic drugs
2. Phenothiazine deaths: A critical review
3. Intramyocardial lesions in patients dying suddenly and unexpectedly
4. Sudden death in phenothiazine therapy: A clinicopathologic study of 12 cases
5. Electrocardiographic changes in patients receiving neuroleptic medication
6. A survey of sudden death associated with the use of antipsychotic or antidepressant drugs: 49 Cases in Finland
7. QTc-interval abnormalities and psychotropic drug therapy in psychiatric patients
8. Drugs, QT interval abnormalities and ventricular arrhythmias
9. Excess risk of myocardial infarction in patients treated with antidepressant medications: Association with use of tricyclic agents
10. Cardiotoxicity more common in thioridazine overdose than with other neuroleptics
11. The potential for QT prolongation and pro-arrhythmia by non-antiarrhythmic drugs: Clinical and regulatory implications: Report on a policy conference of the European Society of Cardiology
12. Committee on Safety of Medicines
13. Committee on Safety of Medicines
14. Ziprasidone hydrochloride approved for treatment of schizophrenia,but with major warning
15. Myocarditis and cardiomyopathy associated with clozapine
16. Myocarditis and cardiomyopathy associated with clozapine use in the United States
17. Fatal cardiac event following initiation of risperidone therapy
18. Risperidone in the elderly: A pharmacoepidemiologic study
19. Overdose profiles of new antipsychotic agents
20. Drug-induced torsades de pointes: From molecular biology to bedside
21. Risk of torsades de pointes with non-cardiac drugs
22. The increasing use of polypharmacotherapy for refractory mood disorder: 22 Years of study
23. Mortality in schizophrenia: Antipsychotic polypharmacy and absence of adjunctive anticholinergics over the course of a 10-year prospective study
24. Sudden death in psychiatric patients
25. Excess mortality of mental disorder
26. Mortality among patients with psychiatric illness: A ten-year case register study in an area with a community-based system of care
27. The relationship of depression to cardiovascular disease: Epidemiology, biology, and treatment
28. Association between depression. and mortality in older adults: The Cardiovascular Health Study
29. Antipsychotics and the risk of sudden cardiac death
30. Hospital use of antipsychotic agents in 1989 and 1993: Stable dosing with decreased length of stay
31. Major depressive disorder in coronary artery disease
32. Depression following myocardial infarction: Impact on 6-month survival
33. Major depressive disorder predicts cardiac events in patients with coronary artery disease
34. Depression and 18-month prognosis after myocardial infarction
35. Electrocardiographic effects of fluoxetine and doxepine in patients with major depressive disorders
36. Death of two subjects due to imipramine and desipramine metabolite accumulation during chronic therapy: A review of the literature and possible mechanisms
37. Torsades de pointes induced by erythromycin
38. Terfenadine-ketoconazone interaction: Pharmacokinetic and electrocardiographic consequences
39. Physical health of people with severe mental illness
40. Sudden cardiac death, genes, and arrhythmogenesis: Consideration of new population and mechanistic approaches from a National Heart, Lung, and Blood Institute workshop, part II
41. Weight gain from novel antipsychotic drugs: Need for action
42. Sudden unexplained death in psychiatric in-patients